The Jeffrey H. Burbank Sells 7,500 Shares of NxStage Medical Inc. (NXTM) Stock

The Jeffrey H. Burbank Sells 7,500 Shares of NxStage Medical Inc. (NXTM) Stock

NxStage Medical Inc. (NASDAQ:NXTM) CEO Jeffrey H. Burbank sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $27.52, for a total value of $206,400.00. Following the completion of the transaction, the chief executive officer now directly owns 875,116 shares of the company’s stock, valued at $24,083,192.32. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Shares of NxStage Medical Inc. (NASDAQ:NXTM) opened at 28.01 on Thursday. NxStage Medical Inc. has a 12 month low of $13.49 and a 12 month high of $28.36. The stock has a 50 day moving average price of $25.96 and a 200-day moving average price of $24.30. The stock’s market cap is $1.81 billion.

Several equities analysts have weighed in on the company. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “strong-buy” rating and set a $24.00 price target for the company in a research report on Thursday, November 3rd. Canaccord Genuity reissued a “buy” rating and set a $28.00 price target on shares of NxStage Medical in a research report on Thursday, November 3rd. Finally, Northland Securities set a $35.00 price target on NxStage Medical and gave the stock a “buy” rating in a research report on Friday, December 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $27.83.

Several institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA increased its stake in NxStage Medical by 57.5% in the second quarter. BNP Paribas Arbitrage SA now owns 5,548 shares of the medical device company’s stock worth $120,000 after buying an additional 2,026 shares during the period. Nisa Investment Advisors LLC increased its stake in NxStage Medical by 1,418.2% in the second quarter. Nisa Investment Advisors LLC now owns 16,700 shares of the medical device company’s stock worth $362,000 after buying an additional 15,600 shares during the period. Bank of Montreal Can purchased a new stake in NxStage Medical during the second quarter worth $14,911,000. California Public Employees Retirement System increased its stake in NxStage Medical by 7.6% in the second quarter. California Public Employees Retirement System now owns 128,800 shares of the medical device company’s stock worth $2,792,000 after buying an additional 9,100 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its stake in NxStage Medical by 1.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 49,876 shares of the medical device company’s stock worth $1,081,000 after buying an additional 640 shares during the period. Institutional investors and hedge funds own 98.74% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

Related posts

Leave a Comment